Why the study?
African swine fever virus causes a fatal disease in domestic swine without effective antiviral drugs, and microtubule-targeting agents have shown potential against various viruses.
Does compound 6b reduce ASFV replication in vitro without cytotoxicity?
Population
In silico screening, ASFV-infected porcine macrophages, Vero cells, and animal models
Comparison
Compound 6b and new compounds targeting the CBS of tubulin
Design
Preclinical in silico screening, in vitro, and in vivo study
Key result
Compound 6b, a new microtubule-stabilizing agent, reduced ASFV replication in a dose-dependent manner (IC50 = 19.5 μM) with no cellular or animal toxicity.
Authors
Loading...
Hypothesis-generating for ASFV antivirals; leaves open translation to in vivo efficacy and clinical use.
Does compound 6b reduce ASFV replication in vitro without cytotoxicity?
Effect estimate: IC50 = 19.5 μM
Compound 6b is a novel microtubule-stabilizing agent that effectively inhibits African swine fever virus replication in vitro without significant cytotoxicity or animal toxicity.
Sirakanyan et al. (2021) studied African swine fever virus (ASFV) infection. Compound 6b was evaluated on ASFV replication (IC50 = 19.5 μM). Compound 6b, a new microtubule-stabilizing agent, reduced ASFV replication in a dose-dependent manner (IC50 = 19.5 μM) with no cellular or animal toxicity.